Numbers first: 15 mg · six weeks · reflux.
I suspect the usual explanation for this is wrong, or at least incomplete.
I am aware this may have a boring answer. I would still like the boring answer stated clearly.
So what is the mechanism, and how well established is it?
six weeks at 15 mg is 42 days at one dose level — and the arithmetic the question hides is that it also moves every dose above 15 mg back by 42 days. Whether that reduces reflux depends on which quantity it tracks. A symptom driven by the dose itself is unchanged by waiting: 15 mg is 15 mg on day 1 and on day 42. A symptom driven by the rate of change has 42 days of no change to settle in, which is the case the hold is actually made for. The distinction is testable on your own record: plot reflux against days-since-last-increase rather than against dose, and if the peaks line up with the increases the hold is doing something. Escalation schedules are set by a prescriber, and nothing here is medical advice.
The honest answer is that going slower costs time and nothing else, since the exposure ceiling is unchanged.
The published tirzepatide schedule steps 2.5, 5, 7.5, 10, 12.5 and 15 mg at four-week intervals, with 2.5 mg as the initiation step rather than a therapeutic one.
| Week | Fraction of steady state | Trough as × dose |
|---|---|---|
| 1 | 50 % | 0.50 |
| 2 | 75 % | 0.75 |
| 3 | 88 % | 0.88 |
| 4 | 94 % | 0.94 |
| 5 | 97 % | 0.97 |
| 6 | 98 % | 0.98 |
This is why a four-week step interval is approximately, but not exactly, steady state.
To be exact about it, liraglutide titrates weekly rather than four-weekly because its half-life is about thirteen hours, so steady state is reached within days. The interval follows the pharmacokinetics in both cases.
Titration schedules in the licensed products were designed specifically to manage gastrointestinal tolerability, and that intent is stated in the clinical development literature.
Stepping back is a normal adjustment, not a failure.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsThis is the single most consequential controllable variable in the whole experience, and people routinely rush it.
Holding a step for eight weeks instead of four is a legitimate approach with no efficacy cost at the destination, and it is what the trials effectively did for anyone who tolerated poorly.
Worth being precise here: titrating downward is available too. Stepping back and holding is a normal adjustment rather than a failure.
Trial data show gastrointestinal adverse events concentrated in the escalation phase and declining at stable doses.
Faster titration does not reach the destination sooner in any way that matters; it reaches the symptoms sooner.
Hold rather than escalate while symptoms are active. Always.
The short version: four-weekly steps for the weekly agents, hold rather than escalate when symptoms are active, and slower is always available.
The dose that produces an acceptable result with acceptable tolerability is the endpoint, not the top of the schedule. A substantial fraction of trial participants did well below the maximum.
Escalating while gastrointestinal symptoms are still active is the commonest avoidable error. Tolerance to the previous step has not developed, and the new step lands on top of it.
Four to five half-lives to steady state is standard first-order pharmacokinetics and gives the four-week interval directly from the one-week half-life.
Slower costs time and nothing else. The ceiling is the same.
edited 19 Jul 2026 by Dr_Nadia_Farsi — updated for the 2026 guidance change
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.